NMP22、BTAstat联合运用诊断膀胱肿瘤

Combined use of NMP22 and BTAstat in the screening and surveillance of bladder tumor

目的探讨NMP22、BTAstat联合检查在膀胱肿瘤诊断和术后随访中的价值。方法对90例怀疑膀胱肿瘤的患者,均在预约膀胱镜检查前行尿NMP22和BTAstat检查。以病理检查为金标准。分析评价NMP22和BTAstat联合检查在膀胱肿瘤诊断中的作用。结果90例中膀胱移行细胞癌41例、泌尿系其他疾病49例。两者联合诊断膀胱肿瘤敏感性90.2%,与膀胱镜(92.7%)比较,差异显著性(P>0.05),特异性77.6%、阳性预测值80.1%、阴性预测值88.8%。结论NMP22和BTAstat联合检查有助于提高膀胱肿瘤早期诊断的能力。

[ Objective ] To assess the value of combining use of NMP22 and BTAstat in screening and surveillance of bladder tumor （BT）. [Methods] NMP22 and BTAstat were carried out for 90 symptomatic patients suspicious of BT or after surgical treatment before cystoscopy . Pathology was used as the gold standard. Analysis the sensitivity（Se）, specificity （Sp）, positive predictive value （PPV） and negative predictive value （NPV） for each and combined using in bladder tumor. [ Results] 41cases of bladder transitional cell carcinoma were diagnosed by pathology. 49 eases were other benign urological diseases .With combined use of 2, the Se （90.2%） was similar to the cystoscopy （92.7%）（ P 〉 0.05）. The combined Sp, PPV, NPV was 77.6%, 80.1%, 88.8%, respectively. [Conclusion] Combined use of NMP22 and BTAstat improved the diagnostic value in early bladder tumor.